InfuSystem Holdings, Inc. (NYSEAMERICAN:INFU) Short Interest Up 6.7% in July

InfuSystem Holdings, Inc. (NYSEAMERICAN:INFU) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 166,200 shares, an increase of 6.7% from the June 30th total of 155,700 shares. Based on an average trading volume of 57,400 shares, the days-to-cover ratio is currently 2.9 days. Currently, 0.9% of the company’s shares are sold short.

Insider Transactions at InfuSystem

In other news, Director Ralph F. Boyd, Jr. bought 4,000 shares of the business’s stock in a transaction dated Thursday, May 23rd. The shares were purchased at an average price of $7.13 per share, for a total transaction of $28,520.00. Following the completion of the acquisition, the director now owns 6,000 shares of the company’s stock, valued at $42,780. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Paul Andrew Gendron acquired 5,000 shares of the stock in a transaction on Monday, May 20th. The stock was acquired at an average price of $6.54 per share, for a total transaction of $32,700.00. Following the completion of the purchase, the director now owns 65,000 shares of the company’s stock, valued at $425,100. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ralph F. Boyd, Jr. purchased 4,000 shares of the business’s stock in a transaction dated Thursday, May 23rd. The shares were purchased at an average price of $7.13 per share, for a total transaction of $28,520.00. Following the acquisition, the director now owns 6,000 shares of the company’s stock, valued at $42,780. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 13,000 shares of company stock worth $87,300. 10.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On InfuSystem

Several hedge funds have recently modified their holdings of the stock. Panagora Asset Management Inc. acquired a new stake in InfuSystem during the second quarter valued at $208,000. ARS Investment Partners LLC increased its position in InfuSystem by 11.4% during the second quarter. ARS Investment Partners LLC now owns 33,510 shares of the medical instruments supplier’s stock worth $229,000 after purchasing an additional 3,422 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new stake in InfuSystem in the second quarter valued at $272,000. Kings Path Partners LLC acquired a new position in shares of InfuSystem in the 2nd quarter worth approximately $514,000. Finally, Bank of New York Mellon Corp boosted its holdings in InfuSystem by 6.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 93,899 shares of the medical instruments supplier’s stock valued at $641,000 after acquiring an additional 5,391 shares during the period. Institutional investors and hedge funds own 71.13% of the company’s stock.

Wall Street Analysts Forecast Growth

INFU has been the subject of several recent analyst reports. Lake Street Capital raised shares of InfuSystem to a “strong-buy” rating in a report on Thursday, May 9th. StockNews.com lowered shares of InfuSystem from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 13th.

InfuSystem Trading Down 4.2 %

NYSEAMERICAN INFU traded down $0.29 on Thursday, reaching $6.61. 49,024 shares of the stock traded hands, compared to its average volume of 50,782. InfuSystem has a 12 month low of $6.25 and a 12 month high of $11.44. The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.57. The firm has a market cap of $140.79 million, a PE ratio of -655,000.00 and a beta of 1.44.

InfuSystem (NYSEAMERICAN:INFU) last issued its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported ($0.05) earnings per share for the quarter. InfuSystem had a return on equity of 0.16% and a net margin of 0.07%. The company had revenue of $32.00 million for the quarter.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.